Virtual reality surgical training wins industry attention with scalable model

Tern plc

A virtual reality training platform developed by Fundamental XR and Orbis International has been awarded Gold in a major technology competition, highlighting how immersive tools are starting to gain traction in global medical education.

This programme, focused on ophthalmic surgery, allows medical trainees to practise procedures in a fully immersive virtual environment, without the limitations of physical equipment, live supervision or real-world patient risk. The result is a more accessible, standardised form of surgical education, especially valuable in countries where hospital training resources are limited or overstretched.

What sets this initiative apart is its focus on real-world application. The technology has been designed to fit the workflow and constraints of medical education systems in lower-resource settings. This combination of technical quality and real-world relevance is what earned the recognition, and it signals a step forward for VR in professional training markets.

Orbis brings decades of experience in eye care and surgical training around the world, while Fundamental XR provides the technical capability to deliver high-fidelity, scalable simulations. Together, they have built a tool that solves a pressing educational problem with modern technology, a clear use case with long-term potential.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search